Trump sends a message to senators with bid to make Lara Trump one of their colleagues: 'Get used to it' READ MORE: Sign up for DailyMail.com's daily political email By GEOFF EARLE, DEPUTY U.S. POLITICAL EDITOR Published: 22:06, 10 December 2024 | Updated: 22:50, 10 December 2024 e-mail View comments Donald Trump 's brash push to have his daughter-in-law appointed to a seat in the Senate is sending a message that isn't being lost on the Republican lawmakers who would serve closely with her. They are already living in Trump's world. Sharing formal luncheons an late-night-amendment votes with his close family member would be just the latest accommodation to it. 'I mean, he’s selling watches,' Republican Sen. Mike Braun of Indiana told DailyMail.com. 'And I think he’s going to keep doing the stuff that for most people, it doesn’t bother half the country. And for the other half, they better get used to it, because the indictment was mostly against their point of view and how this place is run generally,' the Trump ally said. Braun, the governor-elect of Indiana, was referencing the signed gold watches Trump is selling for up to $100,000 – a product that came out months before Trump started selling a $199 fragrance pegged to his visit last weekend to Notre Dame Cathedral. Both product pitches indicate that Trump has no intention of bowing to watchdog groups or historic norms that have shielded presidents from profiting from the office. Florida Gov. Ron DeSantis would have the power to appoint a successor to Sen. Marco Rubio (R-Fla.), who is looking increasingly likely to be confirmed as Secretary of State after the new year. And DeSantis himself could be up for the powerful post of Defense Secretary if Pete Hegseth's nomination should implode – although key Republican senators like Joni Ernst are now supporting the 'process' to confirm him. 'I think he's qualified for the role and I certainly don't start out with any negative disposition,' said Senate Majority Leader Charles Schumer after meeting with Rubio, in a sign he could sail through the chamber. A DeSantis nomination could involve a complex exchange that could still land Lara Trump in the Senate. Rubio himself told DailyMail.com he believes Lara Trump has what it takes to join the Senate. 'I do,' he said. And he said there isn't anything inappropriate with Trump angling on his daughter-in-law's behalf. 'Why would it not be? He’s a resident of Florida on top of being the president-elect. If he has an opinion on who it should be he should share it,' Rubio said. President-elect Donald Trump's push to get his daughter-in-law Lara Trump appointed to the Senate is drawing support from Senate Republicans. Lara Trump, who just announced she has stepped down from her post as co-chair of the Republican National Committee, would bring new blood in the chamber, which is three-quarters male and where there are five octogenarians, 30 members over 70, and 21 over age 65 – even if her children Luke and Carolina are blood relatives of the Article II head of the country. Trump recently spoke to DeSantis about his daughter-in-law, the Wall Street Journal reported Tuesday, at a time when he is attempting to stock his cabinet with loyalists. Read More Donald Trump hawks branded diamond encrusted watches One Republican senator who spoke to DailyMail.com said party members would not harbor concerns about having the president's daughter-in-law sit inside the weekly strategy sessions that senators hold over crab cakes and other regional cuisine. But the senator did raise an issue. 'I think that’s going to be a difficult thing for the Florida governor – she’s from North Carolina,' the senator said. (She is currently a resident of Florida, as is her powerful father-in-law). She gave an interview to the Associated Press Monday where she indicated she was wide open to the post . 'It is something I would seriously consider,' she said. 'I’m being completely transparent, I don’t know exactly what that would look like. And I certainly want to get all of the information possible if that is something that’s real for me. But yeah, I would 100 percent consider it.' Republican voters also like the idea. The power play isn't lost on Senate Democrats, who will soon adjust to minority status in a chamber where Republicans will hold a 53-47 edge after their election pickups. Whoever DeSantis picks would get to serve until 2026, when a special election would be held for the remaining two years of Rubio's term. 'Look, the reality is, it's the governor's appointment. We can comment or have opinions, but we have no impact There’s a new sheriff in town. His name is called Trump,' said Sen. Peter Welch (D-Vt.). Indiana Florida Politics Share or comment on this article: Trump sends a message to senators with bid to make Lara Trump one of their colleagues: 'Get used to it' e-mail Add comment
Trinity Capital Inc. (TRIN) to Issue Quarterly Dividend of $0.51 on January 15thOTTAWA - A Liberal MP says his committee colleagues are wasting time by launching a third inquiry into the former employment minister instead of focusing on important legislation for Indigenous Peoples. Jaime Battiste, who is Mi’kmaq, said there has been an “attack” on fellow Liberal MP Randy Boissonnault, who left his position as employment minister on Wednesday after allegations of shifting claims of Indigenous identity and questions around his past business dealings. Boissonnault has been the subject of two ethics committee probes, and Battiste said a third one by the Indigenous and northern affairs committee is “a waste of time, and it seems to be the Conservatives’ way of ensuring that nothing gets done in the House of Commons.” The Conservatives, NDP and Bloc Québécois all supported pushing ahead with the third study, even after Boissonnault left cabinet. Though Liberal MPs did not object to the motion Thursday, Battiste said the committee’s time would be better spent studying legislation on important issues such as First Nations policing, a modern treaty commissioner and clean water for First Nations. “It’s very much my fear and frustration that politics is now becoming more important at the Indigenous and northern affairs committee than actually Indigenous Peoples that we’re there every day to try to make life better for,” he said. NDP MP Lori Idlout, who is a member of the committee, said Canadians deserve answers and she doesn’t expect the probe to cut into the committee’s other work. “It’s not a waste of time to have MP Boissonnault answer for why his identity kept changing. Pretending to be Indigenous is a serious matter and we need to have him be transparent to all Canadians.” Boissonnault came under intense scrutiny after the National Post reported that a company he previously co-owned described itself as wholly Indigenous-owned in order to apply for government contracts set aside for Indigenous businesses. He has been described as Indigenous multiple times in communications from the Liberal party, and in 2018 referred to himself as “non-status adopted Cree” — a statement he has repeated on other occasions. He also said his great-grandmother was a “full-blooded Cree woman.” He has since clarified that his adoptive mother and brother are Métis, and he apologized for his shifting claims last Friday. The House ethics committee has separately investigated Boissonnault’s past business dealings after media reports alleged he remained involved in the company he co-founded after he was re-elected in 2021 and joined the federal cabinet. Opposition MPs passed a motion in the House of Commons on Tuesday — a day before Boissonnault left cabinet — for the employment minister to appear as a witness to discuss his claims to Indigenous identity. But because Boissonnault is no longer in cabinet, the Liberal chair of the committee ruled Thursday that newly minted Employment Minister Ginette Petitpas Taylor is technically the person the motion called to testify. “I figured this might happen,” said Conservative MP and committee member Jamie Schmale. “If there are games to be played here and we have Minister Petitpas Taylor attend, I don’t think that goes to the spirit of the House order. I don’t think it would be very responsible to go against that ... It’s Randy Boissonault that the House determined it needs and is ordered to appear along with several other witnesses. That’s who we expect to be in that seat.” A new motion from the Conservatives calls directly for Boissonnault to appear at the committee. One of the key concerns raised about Boissonnault in recent weeks is related to the government’s Indigenous business procurement strategy. A directory provides the federal government with names of businesses it could consider using to meet its Indigenous procurement target, which states a minimum five per cent of the total value of government contracts should be held by Indigenous-owned businesses. Indigenous Services Minister Patty Hajdu told a House of Commons committee on Tuesday that the company Boissonnault founded was not listed on that directory. Battiste suggested the committee will now be in a position of determining who is eligible for Indigenous programming and determining who is Indigenous, and as a First Nations person he does not agree with that. “I have a lot of concern because no First Nations, Métis or Inuit in this country are asking committees — who are filled with non-Indigenous Peoples — to determine our identity, who we are.” Schmale and Bloc MP Sebastian Lemire, who is also a member of the committee, did not immediately respond to requests for comment. This report by The Canadian Press was first published Nov. 21, 2024. Note to readers: This is a corrected story. A previous version stated that MPs on the Indigenous and Northern affairs committee passed a motion to have the employment minister appear as a witness at the committee.Maverick McNealy birdies the last hole at Sea Island to finally become PGA Tour winner
Paragon 28 sees $401,384 in stock sales by MVM Partners
US, South Korea Conducting Joint Research To Block North Korean Crypto Heists
Gambling companies spent big to defeat three California lawmakers. ‘We want to be respected’CNN's Wolf Blitzer gives UB football celebrity treatment ahead of final regular-season gameWACO, Texas (AP) — Georgia's Dasha Vidmanova and Columbia's Michael Zheng won NCAA singles tennis titles on Sunday. Vidmanova, a 21-year-old senior from the Czech Republic, beat DJ Bennett of Auburn 6-3, 6-3 for the Bulldogs' first women's singles championship since 2010. Zheng, a 20-year-old junior from Montville, New Jersey, beat Ozan Baris of Michigan State 6-2, 4-6, 6-2 to become the first Ivy League player to collect an NCAA men's singles crown since 1922. The final between Zheng and Baris was the first men's NCAA tennis singles final between two Americans since 2017. More AP tennis: https://apnews.com/hub/tennisEthanol Car Market is Going to Booming Growth 2024-2031 With Future Scope, Demand, Size, Share
Ring of Honor TV live results: International Women’s Cup qualifierThe trade group of Colorado hospitals is preparing for a political battle at the state Capitol to maintain a federal drug discount program that the group says benefits nearly 70 hospitals statewide. Critics of the program known as 340B argue it has been widely abused and misused, particularly by large hospitals. While it is a federal program, Julie Lonborg, senior vice president of Colorado Hospital Association, said her group will turn to the Colorado state legislature next year to push legislation to protect hospitals from losing funding. The program, she said, is under attack by the pharmaceutical industry. The group and officials from several hospitals hosted a virtual roundtable on Dec. 10 to discuss maintaining funding they argued is needed to keep hospitals on track. In the meeting organized by the trade group, Lonborg said 68 of the state’s 88 hospitals qualify for the 340B program. The federal 340B Drug Pricing Program, established in 1992 as part of the Public Health Service Act, allows eligible healthcare organizations to purchase outpatient drugs at a discount from manufacturers. In an email to Colorado Politics, Cara Welch, the group's communications director, said protecting 340B is a priority. No legislation has been drafted yet and no sponsors at the Capitol have been found, Welch said. Welch said that, since 2020, pharmacies have started limiting hospitals' participation in the program, adding that states have oversight, though 340B is a federal program. Last month, a three-member panel attended a healthcare forum in Denver said large hospitals are abusing the program that is supposed to help pay healthcare costs for low-income families. The panel said fixing the program cannot happen at the state level, maintaining Congress must fix it. During the Nov. 12 forum, William Smith, a senior fellow at the Pioneer Institute, said pharmacy benefit managers (PBMs) and large hospitals have learned how to profit from the program. For example, a cancer drug costing around $200,000 is only $25,000 for hospitals with 340B status. However, the hospital is still billing insurance companies for $200,000 and “pocketing $175,000 in profits," he said. “That's really what's driving this program — is the ability of hospitals to arbitrage the discounts,” Smith said. “And what's happened is hospitals have gone out into wealthy neighborhoods and have purchased physician practices, particularly physician practices that prescribe high-cost drugs, like rheumatologists or oncologists, and they bought them up so that they could charge more to the discounts for profit.” Critics also said the program has become mismanaged and underregulated due to staff shortages at the Health Resources and Services Administration, which oversees it. Others said hospitals have not been transparent about using 340B funding. Courtney Christian, deputy vice chair of policy and research for PhRMA, said the solution is not be to eliminate the 340B program because it has value to hospitals when applied correctly, noting that its primary purpose is to help patients in need and support charitable programs. The hospital association said keeping the program is vital. The main question is whether state lawmakers would make changes or leave the issue completely up to the federal government. “The powerful pharmaceutical industry has mounted a coordinated national effort to weaken 340B, even though this discount program accounts for 3% of the drug companies’ profits globally," the association said. "Despite the minimal impact to pharmaceutical companies, 340B is an essential lifeline for 68 participating Colorado hospitals with; 89% of which operate with low or negative margins.” Meanwhile, Kevin Forbush, the 340B program director at Intermountain Health in Brighton, said he disagrees with the assertion that the program does not have oversight, noting he has taken part in audits for the last 10 years. “This is a highly regulated program that’s administered by the federal government, Forbush said. “I, myself have been through six of these audits. They are very intense.” Forbush described a system where hospitals must undergo a process to meet stringent criteria. Under the 340B program, a patient who needs blood thinner medication pays 28 cents when the regular cost is $500; hence, the 340B program, which aims to bring down drug costs, works, he said. Chris Thomas, the president and CEO of Community Hospital in Grand Junction, said hospitals are already operating on thin margins, and “340B funding for us is absolutely critical.” For some hospitals barely operating in the black, hospital officials say losing funding could force them to operate at a deficit. UCHealth Vice President Dan Weaver said that UCHealth is the state’s largest MedCaid provider and that it continues to see the number of uninsured patients grow. “340B is extremely important to us,” he said. “Not only do some of the of our hospitals qualify for 340B because of the amount of uncompensated care that they provide, but 340B makes that uncompensated care possible.” Being in an urban community, Thomas said the Community Hospital is five miles from another hospital and considered too big to be a critical access facility. With 340B funding, Thomas said, the hospital has invested in a better OB and midwife program. “We embed our midwives,” he said. “They go into our safety net clinic on a weekly basis and see patients on a sliding scale. We know that giving prenatal care early and often saves money, saves lives and improves the health of our community.” At the November forum, Jonathan Campbell, the chief science officer for the National Pharmaceutical Council, said those who are abusing the 340B program are costing the healthcare industry an estimated $5 billion.
Houston Texans wide receiver Nico Collins scored a touchdown against the Tennessee Titans in his most recent home game and tossed the ball to a child in the stands pleading for it. On Thursday, Collins told reporters the NFL did not approve and assessed him a fine of about $5,000. "It's for the kids," Collins said. "I seen he was screaming and was thinking, ‘Here you go, big dog. Here's the ball.'" Collins said he was not penalized last season on the handful of occasions he threw a ball into the stands, so he wasn't expecting a fine. But making a child's day was "definitely worth it." The 25-year-old said he plans to appeal the fine, but if it isn't overturned, he'll pay up. "The only thing that matters was making that kid happy," he said. "He ain't never going to forget that moment. So that's all that matters to me." Collins followed up a 92-yard, one-touchdown performance that day against Tennessee with eight receptions for 119 yards last week at Jacksonville. The fourth-year wideout is Houston's leading receiver despite missing five games due to a hamstring injury. He has caught 49 passes for 832 yards and four touchdowns in just eight appearances. --Field Level Media
BSR Real Estate Investment Trust (BSRTF) to Issue Dividend of $0.05 on January 15th
Published 8:50 pm Sunday, December 29, 2024 By Data Skrive There is one game on the college basketball schedule on Monday that feature a ranked team. That matchup is the Alcorn State Braves versus the Ole Miss Rebels. Watch women’s college basketball, other live sports and more on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Use our link to sign up. Catch tons of live women’s college basketball , plus original programming, with ESPN+ or the Disney Bundle.Offsetting NHS funding from existing services to pay for expensive new drugs could be harming the health of the nation, a study suggests. The cost of innovative new medicines “do not always justify the benefits they offer”, researchers warned. They suggest England’s pharmaceutical pricing policy should be reformed “to better serve the health needs” of all NHS patients. However, NHS spending watchdog the National Institute for Health and Care Excellence (Nice) said its role is “vital”, with it helping to prevent a “postcode lottery” in patient access and potentially higher costs. The study, led by academics at the London School of Economics and Political Science (LSE), looked at how many additional years of full health were generated by drugs approved by Nice between 2000 and 2020. The analysis found new medicines led to 3.75 million additional years of full health, costing £75 billion. However, it suggests that redirecting that funding to existing services could have generated five million years of full health. Researchers said that while new drugs “could have benefited patients who received them” access “came at a considerable cost for others who might have missed out on potential health gains due to necessary disinvestment or underinvestment in other forms of care to fund these newly recommended drugs”. Lead author Huseyin Naci, associate professor of health policy at the LSE, added: “New drugs can be a lifeline for patients who have significant unmet clinical needs. “However, innovative drugs are expensive, and their costs do not always justify the benefits they offer.” Academics said the findings relate to Nice’s cost-effectiveness threshold and suggest it should be lowered. Nice advises its committees to consider new drugs as offering value for money to the NHS if they cost less than £20,000 to £30,000 per additional year of full health gained. Prof Naci added: “After more than a decade of underinvestment in the NHS, it may no longer be justifiable to have a Nice threshold that doesn’t reflect the amount the NHS needs to spend to generate health. “Lowering the threshold would allow the NHS to negotiate better prices for new medicines, taking into account not only the benefits to patients receiving these drugs but also the impact on other NHS users who may lose out due to resource reallocation.” Irene Papanicolas, professor of health services, policy and practice at Brown University, said the findings, published in The Lancet, “are reflective of the tight budget of the NHS”. “In this environment, offsetting funding from existing services to pay high prices for new drugs can more adversely affect population health than in health systems where there is greater budgetary flexibility,” she added. Beth Woods, senior research fellow at Centre for Health Economics at University of York, said: “This work shows that there is a need to reform pharmaceutical pricing policy in England to better serve the health needs of all patients served by the NHS.” A spokesperson for Nice said the spending watchdog’s role is “vital” and helps prevent a postcode lottery. “Spending money on new medicines does create an opportunity cost, displacing services elsewhere in the health system,” they said. “That’s why Nice’s role is vital: we carefully evaluate new treatments and recommend only those that offer value-for-money for the taxpayer. “This is especially important during times of significant challenge to the NHS. Every pound of the NHS budget can only be spent once. “If Nice had not recommended these innovative new medicines, they almost certainly would have been used within the NHS anyway. “Without Nice’s input, funding decisions would be taken locally, leading to inequitable patient access – the ‘postcode lottery’ – and potentially higher costs, because multiple local negotiations with pharmaceutical companies may not drive best value for the NHS.”
Clinical Research Organization Global Template Market Set For 9.8% Growth, Reaching $86.33 Billion By 2028
Apple has stopped selling three iPhone models in Europe -- the iPhone 14, iPhone 14 Plus, and the iPhone SE 3rd Generation. Here is why. If you’re in Europe and planning to buy an iPhone 14, iPhone 14 Plus or iPhone SE (3rd generation), then know Apple has officially stopped selling these models in certain regions, including the European Union (EU), Northern Ireland, and Switzerland. The reason? A new EU law requires all electronic devices, including smartphones, to use USB-C charging ports by December 28, 2024. Apple, which traditionally used its own Lightning port, started switching to USB-C with the iPhone 15 series. But older models like the iPhone 14 and iPhone SE still use Lightning ports, so they no longer meet the EU’s requirements. Can You Still Buy Them? Yes, but only for the time being the long term. Even though Apple has pulled these units from its official shops in Europe, you may be able to get them through other dealers. For example, even Amazon Spain could have some stock left. However, this is likely to be a short-lived trick as once the existing stock is sold out, these models are not going to be available in the area anymore. However, if you are outside Europe, for instance in the United States, India or China, there won’t be any changes. Apple still sells the iPhone 14 and the iPhone SE in these markets. What Was The EU’s Motivation To Bring This Law? Implementation of new rules has only one goal, to reduce e-waste as well as consumer’s experience. With one single port, you will no longer have to worry about how many cables you have to carry for various devices. As most Android phones use USB-C already, the effect will only be on Apple and its use of the Lightning connection. Apple, on the other hand, was against the idea while claiming that the Lightning port served its purpose well. But the company has adopted USB-C, first on its new iPhones starting iPhone 15 series, then on its iPads and AirPods. What Does This Mean for the Future? For Apple, this move lines up with its broader strategy. The iPhone SE wasn’t selling well anyway, and there are rumours that a new model with USB-C is in the works for early 2025. This gives Apple a chance to refresh its budget lineup while complying with regulations. For users, there’s no need to worry if you already own a Lightning-port device. Accessories and chargers will still be available for years. But if you’re in Europe and want to buy an iPhone 14 or SE, now’s the time to act before stocks run out. As of now, this regulation only affects Europe. But other regions could follow suit. If you’re considering upgrading your phone, it’s a good idea to keep these changes in mind. Click for more latest Mobile Phone news . Also get top headlines and latest news from India and around the world at News9. Divya is a Senior Sub-Editor with about 3 years of experience in journalism and content writing. Before joining News9live, she had contributed to Times Now and Hindustan Times, where she focused on tech reporting and reviewing gadgets. When she's not working, you can find her indulging in Netflix, expressing her creativity through painting, and dancing.Sable Resources Ltd. ( CVE:SAE – Get Free Report ) fell 16.7% on Friday . The company traded as low as C$0.03 and last traded at C$0.03. 758,789 shares were traded during trading, an increase of 342% from the average session volume of 171,599 shares. The stock had previously closed at C$0.03. Sable Resources Trading Down 16.7 % The firm has a market capitalization of C$7.18 million, a P/E ratio of -0.63 and a beta of 1.08. The stock has a 50-day simple moving average of C$0.04 and a two-hundred day simple moving average of C$0.04. The company has a current ratio of 0.69, a quick ratio of 40.33 and a debt-to-equity ratio of 1.33. About Sable Resources ( Get Free Report ) Sable Resources Ltd. engages in the acquisition, exploration, and development of mineral resource properties in Mexico and Argentina. The company explores for gold, silver, copper, lead, zinc, and other deposits. It holds 100% interests in the Don Julio project covering an area of 63,314 hectares; the El Fierro project covering an area of 58,510 hectares; the El Fierrazo project, the Los Pumas project, and the Laspina project located in San Juan Province, Argentina; and the Vinata project and the El Escarpe project located in Mexico. Recommended Stories Receive News & Ratings for Sable Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sable Resources and related companies with MarketBeat.com's FREE daily email newsletter .